Abstract
Treatment with a daily dose of the aminoglycoside antibiotic gentamicin might improve the life expectancy and quality of life of a significant proportion of patients with Duchenne muscular dystrophy (DMD), according to Lee Sweeney (University of Pennsylvania School of Medicine, Philadelphia, PA, USA). DMD is an X-linked degenerative disorder of muscle that affects about 1 in 3500 male children and is caused by the absence of the protein dystrophin. Using the mdx mouse model, Sweeney and his colleagues showed that a spike of this potent antibiotic has the potential to induce the production of full-length dystrophin in muscle tissue in some DMD patients1xAminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. Barton-Davis, E.R. et al. J. Clin. Invest. 1999; 104: 375–381Crossref | PubMedSee all
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
